SpringWorks Therapeutics, Eli Lilly and Company, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Medical stocks within the last several days.
SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Shares of SpringWorks Therapeutics stock traded up $1.44 during trading on Monday, reaching $46.16. The company's stock had a trading volume of 68,654,638 shares, compared to its average volume of 1,740,554. The company has a 50-day moving average price of $46.20 and a two-hundred day moving average price of $40.64. SpringWorks Therapeutics has a fifty-two week low of $28.21 and a fifty-two week high of $62.00. The firm has a market cap of $3.46 billion, a PE ratio of -13.26 and a beta of 0.79.
Read Our Latest Research Report on SWTX
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Eli Lilly and Company stock traded down $18.14 during midday trading on Monday, hitting $866.40. 1,984,653 shares of the company's stock were exchanged, compared to its average volume of 3,439,259. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a market cap of $821.50 billion, a price-to-earnings ratio of 74.09, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The firm's 50 day simple moving average is $827.69 and its 200 day simple moving average is $817.26.
Read Our Latest Research Report on LLY
UnitedHealth Group (UNH)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.
UNH stock traded down $1.59 during trading on Monday, hitting $417.05. The company had a trading volume of 2,986,273 shares, compared to its average volume of 4,476,700. The firm has a 50-day moving average price of $503.28 and a 200-day moving average price of $534.18. UnitedHealth Group has a 1-year low of $412.02 and a 1-year high of $630.73. The firm has a market cap of $379.61 billion, a PE ratio of 26.90, a price-to-earnings-growth ratio of 1.37 and a beta of 0.61. The company has a quick ratio of 0.91, a current ratio of 0.83 and a debt-to-equity ratio of 0.74.
Read Our Latest Research Report on UNH
See Also
Before you consider SpringWorks Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SpringWorks Therapeutics wasn't on the list.
While SpringWorks Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
